Analyst Ratings and Price Target Adjustments for Blueprint Medicines
As of February 13, 2024, Blueprint Medicines (NASDAQ:BPMC) has received analyst reviews over the past three months, showcasing a diverse ...
Tag: BPMC
JMP Securities Analyst Reiterates Market Outperform Rating and 114 Price Target for Blueprint Medicines
On January 16, 2024, JMP Securities analyst Reni Benjamin expressed his optimism for Blueprint Medicines (NASDAQ:BPMC) by reiterating a Market ...
Diversified Trust Co. Increases Holdings in Blueprint Medicines, Sparking Investor Interest in Precision Therapy Biotech Company
Diversified Trust Co has recently reported an increase in its Blueprint Medicines Co. holdings by 45.7% during the first quarter, ...
Teachers Retirement System of The State of Kentucky Increases Investment in Precision Therapy Company: Blueprint Medicines Co.
On June 19th, 2023, Teachers Retirement System of The State of Kentucky reported that they had lifted their position in ...
Popular News
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
-
NextGen Healthcare Charts Course for Behavioral Health Transformation
-
Regulatory Shift Sparks Potential Breakthrough for DeFi Technologies
